Management

pierre
Pierre Beauparlant, Ph.D.
Chief Business Officer
Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization.  As Chief Business Officer, Dr. Beauparlant is responsible for the development and execution of business strategy for Therillia, as well as the development stage pharmaceutical companies that Therillia manages.

Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities. Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant holds a Ph.D. from McGill University.

Michael Dixon
Michael Dixon, CPA, CA
President and CEO
Michael Dixon has over 18 years of experience working in an executive role for venture-backed companies. Prior to his role in Therillia, Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.
Dr. Louise Proulx
Louise Proulx, Ph.D.,
Chief Development Officer
Dr. Louise Proulx holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm. She has close to 30 years’ experience in research and development management. She has held, over the years, scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice Principal Research at McGill University. She then returned to the pharmaceutical industry where she has been Vice President, Product Development at ViroChem Pharma Inc. She then became Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals. She is now Chief Development Officer at Therillia. Dr. Proulx has been a member of several boards of directors over her career and she is currently a member of the board of directors of the Research Institute of the McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors. She is also member of the Canadian Foundation for Innovation.
Gordon Shore
Gordon Shore, Ph.D.,
Chief Scientific Officer
Gordon Shore, a Professor of Biochemistry and Oncology and member of the Goodman Cancer Research Center at McGill University, is internationally recognized for his research on cell survival and death mechanisms. In 1998, he leveraged this research and co-founded Gemin X Pharmaceuticals Inc. Until 2011 and the acquisition of Gemin X by Cephalon (now Teva), he was a Director and the CSO of the company. He was also interim CEO (2007/8). During this period, Gemin X advanced 2 novel, targeted small molecule drug candidates from concept, through discovery and into late stage clinical development in oncology. He focused additional research efforts both at Gemin X and at McGill to elucidate rational paths to clinical proof of concept studies for these agents.In 2010, Dr. Shore, together with his colleague Anne Roulston, extended such research at McGill, raising grant monies to build an Integrated Functional Genomics Platform that exploits genome-wide approaches focused on synthetic lethality and personalized medicine. The goal of this Integrated Platform is to generate the knowledge and tools to elucidate a clinical path forward for new targeted agents, especially in but not limited to oncology.In 2013, this McGill Platform partnered with Therillia Development Co., where Dr. Shore is CSO, to help guide clinical development strategies for several early stage drug candidates.